Clinical trials: Benign Prostatic Hyperplasia (BPH)
Prostatic Hyperplasia
A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).
Patients who are currently symptomatic and have been diagnosed with BPH by a physician may qualify for this 20-week study. Patients must not be diabetic, must not have prostate cancer and must not have had any surgery to repair…
- Trial name
- NCT00044226
- Testing
- ML-04A
- Where
- 14 sites in United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Milkhaus Laboratory
Prostatic Hyperplasia
SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin
It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the healthy male volunteers under fasting conditions receive, in each period, the test formulation…
- Trial name
- NCT01262989
- Testing
- Test formulation, Reference formulation
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
The purpose of this study is to evaluate the safety and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.
- Trial name
- PLUS-1 (NCT01966614)
- Testing
- PRX302
- Where
- 76 sites in United States, Australia and 4 more
- Volunteers
- 479 people
- Sponsor
- Sophiris Bio Corp
Prostatic Neoplasms, Prostatic Hyperplasia
Prostate Mechanical Imager (PMI) Clinical Bridging Study
The purpose of this study is to evaluate an imaging capability Prostate Mechanical Imager (PMI), a PC-based device utilizing a transrectal probe with pressure sensor arrays and motion tracking system, aimed at providing composite…
- Trial name
- PMI (NCT00822952)
- Where
- 5 sites in United States
- Volunteers
- 71 people
- Sponsor
- Artann Laboratories
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Safety and Effectiveness Study of the Zenflow Spring System
Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.
- Trial name
- BREEZE (NCT04987138)
- Testing
- Zenflow Spring System
- Where
- 7 sites in United States
- Volunteers
- 279 people
- Sponsor
- Zenflow, Inc.
Benign Prostatic Hyperplasia
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
This study is designed to compare safety and efficacy of monotherapy finasteride to combination therapy (finasteride and tamsulosin) in Asian men with benign prostatic hyperplasia (BPH) who are at least 50 years of age or older.
- Trial name
- NCT01534351
- Testing
- Finasteride, Tamsulosin
- Volunteers
- 1 people
- Sponsor
- Merck Sharp & Dohme LLC
Benign Prostate Hyperplasia, Erectile Dysfunction
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of…
- Trial name
- NCT01937871
- Testing
- 5 mg Tadalafil, 0.2 mg Tamsulosin
- Where
- 14 sites in China
- Volunteers
- 909 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.
- Trial name
- NCT00316732
- Testing
- IPSS Questionnaire, EQ-5D Questionnaire
- Where
- 27 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia
To evaluate the efficacy and safety of the Water Vapor Thermal Therapy system for the treatment of Benign Prostatic Hyperplasia under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the…
- Trial name
- NCT06725212
- Testing
- Water Vapor Thermal Ablation, Cystoscopy
- Where
- 10 sites in China
- Volunteers
- 126 people
- Sponsor
- Medtecx Co Ltd.
Prostatic Hyperplasia
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects
The primary objective of this study is to determine the bioavailability of a FDC capsule formulation of dutasteride and tamsulosin hydrochloride (0.5 milligram [mg]/0.2 mg) relative to coadministration of one dutasteride 0.5 mg…
- Trial name
- NCT02509104
- Testing
- FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin
To investigate the effects of a single dose of sildenafil (100 mg) or placebo on blood pressure and pulse rate in subjects taking doxazosin for benign prostatic hyperplasia (BPH).
- Trial name
- NCT00645034
- Testing
- sildenafil
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Benign Prostatic Hyperplasia
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
The purpose of this study is to evaluate the safety, tolerability and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.
- Trial name
- NCT01454349
- Testing
- PRX302
- Where
- 15 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sophiris Bio Corp
Benign Prostatic Hyperplasia
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
- Trial name
- NCT00224133
- Testing
- Silodosin
- Where
- 79 sites in United States
- Volunteers
- 661 people
- Sponsor
- Watson Pharmaceuticals
Prostatic Hyperplasia
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
This study will be an open-label, randomized, single dose, two-period crossover study to determine the bioavailability of a fixed dose combination capsule formulation of dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg)…
- Trial name
- ARI114694 (NCT01254071)
- Testing
- Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
- Where
- Australia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
The primary objective of this study is to assess the safety and tolerance of transurethral photodynamic therapy (PDT) with QLT0074. Secondary objectives are: 1.
- Trial name
- NCT00077012
- Testing
- QLT0074, Photodynamic therapy
- Where
- 7 sites in United States, Canada
- Sponsor
- QLT Inc.
Benign Prostatic Hyperplasia
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such…
- Trial name
- NCT00848081
- Testing
- Tadalafil
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 318 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia
To evaluate the improvement in symptoms of Benign Prostatic Hyperplasia (BPH) according to the Prostate Symptom Score (IPSS) and Quality- of- Life (QoL) index after add- on therapy of Umooze twice daily administration for 56 days…
- Trial name
- NCT02313233
- Testing
- Umooze
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Golden Biotechnology Corporation
Benign Prostatic Hyperplasia
RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up
The objective of the RELIEF Study is to compare the safety, effectiveness and patient experience outcomes in real-world subjects treated with different modalities for symptomatic BPH.
- Trial name
- RELIEF (NCT05784558)
- Testing
- UroLift System, Watchful Waiting or BPH Medications, Other Surgical Intervention
- Where
- United States
- Sponsor
- NeoTract, Inc.
Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. (BENIPRO)
The clinical trial to evaluate the fixed-dose combination (N0728), with the aim of providing the Brazilian market with an alternative, potentially effective, safe and convenient therapeutic approach for the treatment of Lower…
- Trial name
- BENIPRO (NCT06546735)
- Testing
- N0728, Vesomni®
- Where
- Brazil
- Volunteers
- 816 people
- Sponsor
- Eurofarma Laboratorios S.A.